In this issue:
MSI detection using cfDNA
Maintenance therapy with panitumumab in mCRC
Atezolizumab with or without cobimetinib in mCRC
Regorafenib dose-optimisation in mCRC
Optimal scheduling of chemoradiotherapy in rectal cancer
Predictive value of consensus molecular subtypes in mCRC
Characterisation of early-onset CRC
Tumour subtype and survival after recurrence
Predictive potential of TMB in mCRC
Higher chemotoxicity rates in female patients
Please login below to download this issue (PDF)